AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nektar Therapeutics Soars 156.5% on Positive Atopic Dermatitis Study Results
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jun 24, 2025 8:12 am ET1min read
Nektar Therapeutics' stock surged 156.5% in pre-market trading on June 24, 2025, driven by significant positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in treating atopic dermatitis.
Nektar Therapeutics announced that its Phase 2b REZOLVE-AD study of rezpegaldesleukin
all key endpoints, demonstrating the drug's efficacy in treating moderate-to-severe atopic dermatitis. This study is part of the company's broader immunology pipeline, which includes three separate Phase 2 studies focusing on ResPEGaldu leukin.The company is also evaluating rezpegaldesleukin in alopecia areata, with Phase 2b data expected in the fourth quarter of 2025.
plans to continue monitoring patients in these studies to gather more comprehensive data on the drug's long-term effects and efficacy.Nektar Therapeutics is in a strong financial position, with a cash runway extending into the fourth quarter of 2026. The company is progressing with IND-enabling studies for its TNFR2 agonist antibody program, Nectar 165, and expects to submit an IND filing in 2025. Additionally, Nektar Therapeutics has a collaboration with the Fred Hutchinson Cancer Center, with data from their study being presented at the European Hematology Association congress.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Sable Offshore Soars 5.82% as Private Placement and Policy Tailwinds Drive Pre-Market Rally
Dec.12 2025
Mastercard Inc. Surges 4.55% as Fintech Optimism and AI Expansion Drive Pre-Market Rally
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet